Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

AtriCure (ATRC) EBITDA (2016 - 2025)

AtriCure (ATRC) has disclosed EBITDA for 16 consecutive years, with $1.7 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 110.63% to $1.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$9.8 million through Dec 2025, up 77.99% year-over-year, with the annual reading at -$9.8 million for FY2025, 77.99% up from the prior year.
  • EBITDA for Q4 2025 was $1.7 million at AtriCure, up from -$443000.0 in the prior quarter.
  • The five-year high for EBITDA was $97.0 million in Q3 2021, with the low at -$17.7 million in Q1 2022.
  • Average EBITDA over 5 years is -$4.1 million, with a median of -$8.2 million recorded in 2023.
  • The sharpest move saw EBITDA skyrocketed 2122.14% in 2021, then tumbled 189.4% in 2023.
  • Over 5 years, EBITDA stood at -$14.5 million in 2021, then surged by 79.48% to -$3.0 million in 2022, then crashed by 189.4% to -$8.6 million in 2023, then tumbled by 91.39% to -$16.5 million in 2024, then surged by 110.63% to $1.7 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at $1.7 million, -$443000.0, and -$5.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.